First Trimester Sex Hormone-Binding Globulin and Subsequent Development of Preeclampsia or Other Adverse Pregnancy Outcomes
Authors:
- Kevin SpencerKSKevin Spencer
- Christina K. H. YuCYChristina K. H. Yu
- George RembouskosGRGeorge Rembouskos
- Renu BindraRBRenu Bindra
- Kypros H. NicolaidesKNKypros H. Nicolaides
- 1 January 2005
- journal article
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 24 (3) , 303-311
Abstract
To investigate whether first trimester maternal serum sex hormone-binding globulin (SHBG) concentrations are altered in women who subsequently develop preeclampsia or other pregnancy complications. Women undergoing first trimester combined ultrasound and biochemical screening for chromosomal anomalies. We searched the database and identified 32 pregnancies resulting in miscarriage, 64 pregnancies with preexisting or gestational diabetes mellitus, 107 with fetal growth restriction, 103 with preeclampsia, 64 with pregnancy-induced hypertension, and 26 with spontaneous preterm delivery. We also selected 400 controls from among the population of pregnancies that had a delivery of a normal baby with no pregnancy complications. Maternal serum SHBG concentrations were measured retrospectively using a competitive chemiluminescent immunoassay. The levels between those with normal outcome and those resulting in adverse outcome were compared. The median maternal serum SHBG concentration was not significantly different from controls, in those that subsequently developed preeclampsia (median MoM 1.05), non-proteinuric hypertension (median MoM 0.94) or preterm delivery (median MoM 1.15). The levels were significantly lower in those with diabetes (median MoM, 0.81 p=0.0005) and those pregnancies resulting in miscarriage (median MoM 0.80, p=0.008). First trimester maternal serum SHBG concentrations are no different from controls in women who subsequently develop preeclampsia, pregnancy-induced hypertension, fetal growth restriction, or preterm delivery. Levels are reduced in those who subsequently miscarry or in those presenting with diabetes.Keywords
This publication has 24 references indexed in Scilit:
- First-trimester maternal serum activin A in pre-eclampsia and fetal growth restrictionThe Journal of Maternal-Fetal & Neonatal Medicine, 2004
- The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre‐eclampsiaUltrasound in Obstetrics & Gynecology, 2003
- Second-trimester uterine artery Doppler screening in unselected populations: a reviewThe Journal of Maternal-Fetal & Neonatal Medicine, 2002
- Screening for pre‐eclampsia and fetal growth restriction by uterine artery Doppler at 11–14 weeks of gestationUltrasound in Obstetrics & Gynecology, 2001
- Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsiaHuman Reproduction, 2000
- Insulin Resistance Syndrome in PreeclampsiaSeminars in Reproductive Medicine, 1998
- Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant womenObstetrics & Gynecology, 1995
- Hyperinsulinemia and insulin resistance are associated with preeclampsia in African-AmericansAmerican Journal of Hypertension, 1995
- Glucose intolerance as a predictor of hypertension in pregnancy.Hypertension, 1994
- Sera from preeclamptic women increase the content of triglycerides and reduce the release of prostacyclin in cultured endothelial cellsThrombosis Research, 1991